Answers are grounded in this paper and cite their sources.
Tumor recurrence and resistance to therapy remain challenging issues in oncology. Various theories have been tested, including the stem cell hypothesis, but conflicting results were obtained, and are not applicable to all tumors types. We have addressed an overarching theory focused on cell “survivology” in cancer, and analyzed the existing information on the involvement of the cytoprotective transcription factor NRF2 in tumor progression, tumorigenicity and radio-resistance, with special emphasis on cancer stem cells (CSCs). The review is focused on NRF2-mediated responses of tumor cells under the pressure of selective intracellular and microenvironmental forces that shape their genotype and phenotype, deciding which cells survive and which ones die. The cytoprotection provided by NRF2 distinctively to normal and tumor cells, the common and unique mechanisms accounting for the survival and evolution of tumor cells and CSCs in the harsh tumor environment, including the particular NRF2-driven hallmark features of CSCs in the context of radiotherapy, are emphasized. Finally, existing natural compounds and small molecules showing at preclinical and clinical level an inhibitory action on NRF2 are revised. Altogether, the review highlights that NRF2 might be considered as an oncogenic marker with clinical prognostic value for disease evolution and response to radiotherapy-based treatment strategies.
No takes yet. Share an insight, caveat, or question.
Manda et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: